Ausgabe 2/2023
Inhalt (12 Artikel)
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
James J. Harding, Christiane Jungels, Jean-Pascal Machiels, David C. Smith, Chris Walker, Tao Ji, Ping Jiang, Xin Li, Ekaterine Asatiani, Eric Van Cutsem, Ghassan K. Abou-Alfa
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
Ping-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, Chung-Shu Lee, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Shih-Hong Li, Ho-Wen Ko, Cheng-Ta Yang, Chin-Chou Wang
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Lorenza Rimassa, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
Karolina Piejko, Bożena Cybulska-Stopa, Marcin Ziętek, Robert Dziura, Łukasz Galus, Natasza Kempa-Kamińska, Barbara Ziółkowska, Ewa Rutkowska, Tomasz Kopciński, Tomasz Kubiatowski, Wiesław Bal, Rafał Suwiński, Jacek Mackiewicz, Grażyna Kamińska-Winciorek, Anna M. Czarnecka, Piotr Rutkowski
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma
Nuri Lee, Jae Lyun Lee, Ju-Yeun Lee
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
Klara Dorman, Danmei Zhang, Kathrin Heinrich, Laurens Reeh, Lena Weiss, Michael Haas, Georg Beyer, Daniel Rössler, Elisabetta Goni, Bernhard W. Renz, Jan G. D’Haese, Wolfgang G. Kunz, Max Seidensticker, Stefanie Corradini, Maximilian Niyazi, Steffen Ormanns, Jörg Kumbrink, Andreas Jung, Frederick Klauschen, Jens Werner, Julia Mayerle, Michael von Bergwelt-Baildon, Stefan Boeck, Volker Heinemann, C. Benedikt Westphalen
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer
Maureen Caligiuri, Grace L. Williams, Jennifer Castro, Linda Battalagine, Erik Wilker, Lili Yao, Shawn Schiller, Angela Toms, Ping Li, Eneida Pardo, Bradford Graves, Joey Azofeifa, Agustin Chicas, Torsten Herbertz, Maria Lai, Joel Basken, Kenneth W. Wood, Qunli Xu, Sylvie M. Guichard
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence
Simon Fung, Hannah A. Blair
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
Yahiya Y. Syed
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Sanjay Popat, Myung-Ju Ahn, Simon Ekman, Natasha B. Leighl, Suresh S. Ramalingam, Thanyanan Reungwetwattana, Shankar Siva, Masahiro Tsuboi, Yi-Long Wu, James Chih-Hsin Yang